抗体部门
抗体药物复合体5月3日～4日
属临床开发后期阶段的抗体药物复合体(ADC)，对于充实性肿瘤与血液肿瘤双方，呈现出有希望的治疗效果。藉由特异性、效能、连接子技术、复合体部位设计、医药品的化学量与排列等参数的最适化，ADC达到大幅度的进化。本学会将介绍次世代ADC的设计与表现、活用从成功背后所进展开发的临床候补所获得最新知识的方法等。
第1天 | 第2天
5月3日, 星期四
12:00 pm Registration
1:30 Chairperson's Opening Remarks
Pamela A. Trail, Ph.D., Vice President, Oncology, Regeneron Pharmaceuticals, Inc.
» 1:40 Featured Speaker
Lessons Learned from the Clinic – T-DM1 and Beyond
John Lambert, Ph.D., CSO, ImmunoGen, Inc.
Since 1999, a number of antibody-maytansinoid conjugates (AMCs) have entered clinical testing, with the most advanced of these, T-DM1 and SAR3419, attracting attention for their efficacy and tolerability profile. Lessons learned from earlier AMCs helped inform the design of these compounds, and this body of knowledge that can be applied to AMC design continues to expand and will be discussed.
|
» 2:10 Featured Speaker
The Development of ADCs at Seattle Genetics
Jonathan Drachman, M.D., Senior Vice President, Research and Translational Medicine, Seattle Genetics
Antibody-drug conjugates (ADCs) represent an important class of new cancer therapeutics under development. The deceptively simple concept of targeted drug delivery has been an elusive goal for decades but has been realized with the approval of brentuximab vedotin (ADCETRIS).The current approach to designing empowered antibodies and testing them both pre-clinically and clinically will be discussed.
|
2:40 Sponsored Presentations (Opportunities Available)
3:10 Refreshment Break in the Exhibit Hall with Poster Viewing
4:00 Clinical Case Study
Anne Bousseau, M.D., Head, Early Development Projects, Global Oncology, Sanofi-Aventis
4:30 Antibody-Drug Conjugates: Pre-Clinical Evaluation of a Novel Target
Andrew Simmons, Ph.D., Associate Director, Oncology, Takeda California
5:30-8:30 pm Recommended Dinner Short Course*
SC14 Antibody Conjugate Therapeutics: Potential and Challenges
*Separate registration required.
|
第1天 | 第2天
.jpg "Pharma-Bio Partnsering Forum")